 LOS ANGELES--BUSINESS WIRE--- CDXC nicotinamideriboside--ChromaDex Corp. NASDAQ:CDXC today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen patented nicotinamide riboside, or NR in various health outcomes. Through the industry-leading ChromaDex External Research Program CERPTM, ChromaDex supplies Niagen to researchers around the world at no cost to help advance the understanding of NRs impact on various age-related health cond 